This phase I/II trial is testing the safety of an immunotherapy (Nivolumab) for patients whose blood cancer has relapsed following blood or bone marrow transplantation.
This trial is treating patients with blood cancer.
This is a systemic therapy trial.
You may be able to join this trial if:
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
Pilot study of the tolerability of nivolumab for relapsed or residual haematological malignancies after allogeneic haematopoietic stem cell transplantation
Bristol-Myers Squibb (BMS)
Other Non-Commercial Sponsor
All participants in this non-randomised trial will receive intravenous Nivolumab (3mg/kg) every two weeks for up to 48 weeks.
Recruiting Hospitals Read More